11/18
07:45 am
nlsp
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders [Yahoo! Finance]
Medium
Report
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders [Yahoo! Finance]
11/18
07:30 am
nlsp
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
Medium
Report
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
11/4
07:00 am
nlsp
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
Medium
Report
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
10/28
07:00 am
nlsp
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
Low
Report
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
10/21
07:00 am
nlsp
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
High
Report
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
10/15
07:00 am
nlsp
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
High
Report
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
9/25
08:00 am
nlsp
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
Low
Report
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split